Cytel | Investments | Nordic Capital

Cytel

Pharmaceutical Technology and Advanced Analytics

Cytel is one of the leading global providers of clinical trial design SaaS software, biometric services and advanced analytics, focusing on optimising clinical trials and helping pharmaceutical companies to unlock the full potential of their clinical and real-world data.

Company Background

  • Cutting-edge clinical trial optimisation technologies that harness the full value of clinical and real-world data.
  • Pioneering role in developing and delivering innovative quantitative methods to biotech and pharmaceutical companies.
  • Combination of advanced software platform and leading biometrics services offerings.

Vision & Outlook

  • Actively support and accelerate its next phase of growth and innovation by investing in Cytel's business and software offering.
  • Leverage the company's full potential to increase speed, productivity and efficiency of clinical trials to improve human health by transforming intelligence into confident decisions.
Cytel Logo Transparent

SECTOR

Technology & Payments

Healthcare

REVENUES 2023

EUR 265 million

EMPLOYEES

1,610

OWNERSHIP

Fund X

INVESTMENT DATE

2021

HEAD OFFICE

Waltham, Massachusetts, USA

MANAGEMENT

Jovan Willford

CEO

Jorge Gomez

CFO

RESPONSIBLE ADVISOR

Daniel Berglund

Partner | Co-Head of Healthcare | Head of U.S.

Nordic Capital's Technology & Payments focus

Having invested in the sector for more than two decades, Nordic Capital is one of the most experienced Technology & Payments investors in Northern Europe. Focus is set on companies with great potential to drive superior growth and benefit from fundamental market trends.

Learn more here: